There was a clear trend towards a mean increase in VA from baseline for patients in the ACP 0.3, 1 and 2 mg dose groups at all time points and at the end of the study at week 24 ( online supplemental table 2, figure 2A ).
← all excerpts
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study.
1
—
—